Updates in the Management of Hairy Cell Leukemia

home / peer-exchange / updates-in-the-management-of-hairy-cell-leukemia

EP. 1: Introduction and Epidemiology of Hairy Cell Leukemia

By Steven Coutre, MD, Stanford University Medical Center
Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

June 30th 2020

EP. 2: Molecular Genetic Changes for Hairy Cell Leukemia

By Steven Coutre, MD, Stanford University Medical Center
Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

June 30th 2020

EP. 3: Signs and Tests for Diagnosis and Prognosis of HCL

By Steven Coutre, MD, Stanford University Medical Center
Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

June 30th 2020

EP. 4: Differential Diagnosis and Molecular Tests in Identifying HCL

By Steven Coutre, MD, Stanford University Medical Center
Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

June 30th 2020

EP. 5: Determining When to Treat and First-Line Therapy for HCL

By Steven Coutre, MD, Stanford University Medical Center
Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

June 30th 2020

EP. 6: Combination First-line Therapy in Hairy Cell Leukemia

By Steven Coutre, MD, Stanford University Medical Center
Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

June 30th 2020

EP. 7: When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL

By Steven Coutre, MD, Stanford University Medical Center
Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

June 30th 2020

$Historical Treatment for Relapsed/Refractory HCL$

EP. 8: Historical Treatment for Relapsed/Refractory HCL

By Steven Coutre, MD, Stanford University Medical Center
Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

June 30th 2020

$Landscape Change in the Treatment of Relapsed/Refractory HCL$

EP. 9: Landscape Change in the Treatment of Relapsed/Refractory HCL

By Steven Coutre, MD, Stanford University Medical Center
Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

June 30th 2020

EP. 10: The Role of CD22-targeted Immunotoxins in HCL

By Steven Coutre, MD, Stanford University Medical Center
Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

June 30th 2020

$Treatments for Relapsed/Refractory HCL in Pipeline$

EP. 11: Treatments for Relapsed/Refractory HCL in Pipeline

By Steven Coutre, MD, Stanford University Medical Center
Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

June 30th 2020

EP. 12: Advice for Community Oncologists on Treating HCL

By Steven Coutre, MD, Stanford University Medical Center
Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center

June 30th 2020

Latest Conference Coverage

Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

View More Latest Conference Coverage

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512